THIS week's contribution is from Carl Gibson CEO Complementary Medicines Australia (CMA): Encouraging Research in Complementary Medicines - One of the recent amendments made to the Therapeutic Goods Act 1989 implements a new intermediate pathway for including a product on the Australian Register of Therapeutic Goods.
This 'Assessed' pathway will sit between Aust L listed products and Aust R registered products and will provide the ability for complementary medicines to make intermediate health claims up to health benefits for serious diseases.
It will also include a much needed and long overdue protection for propriety research and clinical trials, encouraging industry investment in research and product innovation.
Australia already holds major potential to be an international leader in complementary medicines research, and this pathway will further support translation of complementary medicines research into both commercial and health policy outcomes.
It will also help Australia to meet the growing international demand for high-quality, evidence-based complementary medicines and natural health products.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Apr 18
